Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients with DLBCL

Trial Identifier:	D8227C00002
Sponsor:	AstraZeneca
NCTID::	NCT05952024
Start Date:	March 2024
Primary Completion Date:	September 2027
Study Completion Date:	September 2027
Condition:	Lymphoma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.